Home › Companies › Roivant Sciences Ltd. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Roivant Sciences Ltd.’s Form 8-K, filed September 11, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of September 10, 2025: 5 items on Roivant Sciences Ltd.’s Form 8-K, filed September 11, 2025: 3 elected · 2 approved.
Significant dissent: 3 directors (29.4%, 26.5%, 26.4% against); 1 say-on-pay vote (60.9% support).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Rubric Capital (13F, 1.0%, as of September 30, 2026) · Two Seas Capital LP (13F, 1.0%, as of September 30, 2026)
Explore Roivant Sciences Ltd. in the interactive database Compare manager voting policies
These tallies are Roivant Sciences Ltd.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed September 11, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Matthew Gline | 430,013,727 | -- | -- | 154,432,135 | 44,227,813 | 74% | Elected | — |
| Elect Director: Keith Manchester | 412,869,513 | -- | -- | 171,576,349 | 44,227,813 | 71% | Elected | — |
| Elect Director: Melissa Epperly | 429,542,705 | -- | -- | 154,903,157 | 44,227,813 | 73% | Elected | — |
| 2. The appointment of Ernst & Young LLP ("EY") to serve as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2026, and to appoint EY as the Company's auditor for statutory purposes under the Bermuda Com | 628,068,956 | 479,264 | 125,455 | -- | -- | 99.9% | Approved | a majority of the votes cast |
| 3. On a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, including the compensation tables and related narrative disclosures | 316,651,402 | 203,244,184 | 64,550,276 | -- | 44,227,813 | 61% | Approved | — |
Source: Roivant Sciences Ltd., Form 8-K, filed with the SEC on September 11, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
295 asset managers disclosed a vote on at least one Roivant Sciences Ltd. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 9 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Description as filed by funds: To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Matthew Gline
Roivant Sciences Ltd.’s own tally for this item (“Elect Director: Matthew Gline”): 430,013,727 for, 154,432,135 withheld, per its Form 8-K filed September 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “(1) Shareholders re-elected the individuals named below to serve as Class I directors of the Company, to hold office until the date of the annual general meeting of shareholders following the fiscal year ending March 31, 2028, and until their successors are duly elected and qualified, or until such…”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 93,276,845 for, 34,310,335 withheld, 1,462,797 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 38,008,316 | 0 | 8 | 0 | For |
| Fidelity | 6,394,753 | 0 | 0 | 27,552,227 | Mixed |
| BlackRock | 17,505,672 | 0 | 0 | 0 | For |
| Morgan Stanley | 8,789,842 | 0 | 0 | 7,964 | For |
| State Street | 4,990,116 | 0 | 0 | 0 | For |
| Charles Schwab | 2,865,389 | 0 | 0 | 0 | For |
| TIAA | 2,217,521 | 0 | 0 | 0 | For |
| Transamerica | 2,078,277 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 2,000,000 | 0 | 0 | 0 | For |
| WisdomTree | 0 | 0 | 0 | 1,767,115 | Withhold |
| Goldman Sachs | 1,660,066 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 1,562,980 | Withhold |
| Equitable | 1,526,704 | 0 | 0 | 0 | For |
| TIFF INVESTMENT PROGRAM | 1,403,699 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,047,664 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 782,901 | 0 | Abstain |
| Brighthouse | 575,835 | 0 | 0 | 157,665 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 571,010 | Withhold |
| John Hancock | 18,400 | 0 | 404,333 | 0 | Abstain |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 395,758 | Withhold |
| Columbia Threadneedle | 376,695 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 338,181 | Withhold |
| JPMorgan | 294,292 | 0 | 0 | 0 | For |
| Northern Trust | 288,515 | 0 | 0 | 0 | For |
| BNY Mellon | 0 | 0 | 0 | 266,779 | Withhold |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
71% Majority: yes · of votes cast
Description as filed by funds: To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Keith Manchester
Roivant Sciences Ltd.’s own tally for this item (“Elect Director: Keith Manchester”): 412,869,513 for, 171,576,349 withheld, per its Form 8-K filed September 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “(1) Shareholders re-elected the individuals named below to serve as Class I directors of the Company, to hold office until the date of the annual general meeting of shareholders following the fiscal year ending March 31, 2028, and until their successors are duly elected and qualified, or until such…”
Support: 71% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 87,230,772 for, 40,356,407 withheld, 1,462,798 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 38,008,315 | 0 | 9 | 0 | For |
| Fidelity | 6,394,753 | 0 | 0 | 27,552,227 | Mixed |
| BlackRock | 17,505,672 | 0 | 0 | 0 | For |
| Morgan Stanley | 8,789,842 | 0 | 0 | 7,964 | For |
| State Street | 0 | 0 | 0 | 4,990,116 | Withhold |
| Charles Schwab | 2,865,389 | 0 | 0 | 0 | For |
| TIAA | 2,217,521 | 0 | 0 | 0 | For |
| Transamerica | 2,078,277 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 2,000,000 | 0 | 0 | 0 | For |
| WisdomTree | 0 | 0 | 0 | 1,767,115 | Withhold |
| Goldman Sachs | 1,660,066 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 1,562,980 | Withhold |
| Equitable | 1,095,062 | 0 | 0 | 431,642 | Mixed |
| TIFF INVESTMENT PROGRAM | 1,403,699 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,047,664 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 782,901 | 0 | Abstain |
| Brighthouse | 575,835 | 0 | 0 | 157,665 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 571,010 | Withhold |
| John Hancock | 18,400 | 0 | 404,333 | 0 | Abstain |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 395,758 | Withhold |
| Columbia Threadneedle | 376,695 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 338,181 | Withhold |
| JPMorgan | 294,292 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 288,515 | Withhold |
| BNY Mellon | 0 | 0 | 0 | 266,779 | Withhold |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
73% Majority: yes · of votes cast
Description as filed by funds: To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Melissa Epperly
Roivant Sciences Ltd.’s own tally for this item (“Elect Director: Melissa Epperly”): 429,542,705 for, 154,903,157 withheld, per its Form 8-K filed September 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “(1) Shareholders re-elected the individuals named below to serve as Class I directors of the Company, to hold office until the date of the annual general meeting of shareholders following the fiscal year ending March 31, 2028, and until their successors are duly elected and qualified, or until such…”
Support: 73% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 92,845,203 for, 34,741,977 withheld, 1,462,797 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 38,008,316 | 0 | 8 | 0 | For |
| Fidelity | 6,394,753 | 0 | 0 | 27,552,227 | Mixed |
| BlackRock | 17,505,672 | 0 | 0 | 0 | For |
| Morgan Stanley | 8,789,842 | 0 | 0 | 7,964 | For |
| State Street | 4,990,116 | 0 | 0 | 0 | For |
| Charles Schwab | 2,865,389 | 0 | 0 | 0 | For |
| TIAA | 2,217,521 | 0 | 0 | 0 | For |
| Transamerica | 2,078,277 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 2,000,000 | 0 | 0 | 0 | For |
| WisdomTree | 0 | 0 | 0 | 1,767,115 | Withhold |
| Goldman Sachs | 1,660,066 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 1,562,980 | Withhold |
| Equitable | 1,095,062 | 0 | 0 | 431,642 | Mixed |
| TIFF INVESTMENT PROGRAM | 1,403,699 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,047,664 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 782,901 | 0 | Abstain |
| Brighthouse | 575,835 | 0 | 0 | 157,665 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 571,010 | Withhold |
| John Hancock | 18,400 | 0 | 404,333 | 0 | Abstain |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 395,758 | Withhold |
| Columbia Threadneedle | 376,695 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 338,181 | Withhold |
| JPMorgan | 294,292 | 0 | 0 | 0 | For |
| Northern Trust | 288,515 | 0 | 0 | 0 | For |
| BNY Mellon | 0 | 0 | 0 | 266,779 | Withhold |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
61% Approved · of votes cast
Prior year: 89.3% for (September 10, 2024 meeting) ▼ 28.4 pts
Description as filed by funds: To cast a non-binding, advisory vote to approve the compensation of our named executive officers.
Roivant Sciences Ltd.’s own tally for this item (“3. On a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, including the compensation tables and related narrative disclosures”): 316,651,402 for, 203,244,184 against — passed, per its Form 8-K filed September 11, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(3) Shareholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, including the compensation tables and related narrative disclosures.”
Support: 61% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,829 | 38,002,496 | 0 | 0 | Against |
| Fidelity | 0 | 33,946,980 | 0 | 0 | Against |
| BlackRock | 1,344,557 | 16,161,115 | 0 | 0 | Mixed |
| Morgan Stanley | 8,789,842 | 7,964 | 0 | 0 | For |
| State Street | 0 | 4,990,116 | 0 | 0 | Against |
| Charles Schwab | 0 | 2,865,389 | 0 | 0 | Against |
| TIAA | 2,217,521 | 0 | 0 | 0 | For |
| Transamerica | 2,078,277 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 2,000,000 | 0 | 0 | 0 | For |
| WisdomTree | 0 | 1,767,115 | 0 | 0 | Against |
| Goldman Sachs | 1,660,066 | 0 | 0 | 0 | For |
| Dimensional | 0 | 1,562,980 | 0 | 0 | Against |
| Equitable | 925,183 | 601,521 | 0 | 0 | Mixed |
| TIFF INVESTMENT PROGRAM | 0 | 1,403,699 | 0 | 0 | Against |
| T. Rowe Price | 0 | 1,047,664 | 0 | 0 | Against |
| Jackson National | 0 | 782,901 | 0 | 0 | Against |
| Brighthouse | 575,835 | 157,665 | 0 | 0 | Mixed |
| AIG/SunAmerica | 0 | 571,010 | 0 | 0 | Against |
| John Hancock | 0 | 422,733 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 395,758 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 376,695 | 0 | 0 | Against |
| Delaware/Macquarie | 0 | 338,181 | 0 | 0 | Against |
| JPMorgan | 0 | 294,292 | 0 | 0 | Against |
| Northern Trust | 0 | 288,515 | 0 | 0 | Against |
| BNY Mellon | 0 | 266,779 | 0 | 0 | Against |
Fund voting reports, all 71 managers: 19,804,659 for, 109,161,237 against, 84,082 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD | 0 | 0 | 59,036,571 | 0 | Abstain |
| Fidelity | 0 | 53,201,296 | 0 | 0 | Against |
| VIKING GLOBAL INVESTORS LP | 30,322,047 | 0 | 0 | 0 | For |
| QVT Financial LP | 29,381,635 | 0 | 0 | 0 | For |
| Morgan Stanley | 27,768,773 | 0 | 0 | 0 | For |
| State Street | 7,595 | 13,133,518 | 0 | 0 | Against |
| BlackRock | 336,228 | 12,110,509 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 7,443,269 | 0 | 0 | Against |
| Two Seas Capital LP | 5,885,523 | 0 | 0 | 0 | For |
| Capital Group | 0 | 0 | 4,832,642 | 0 | Abstain |
| PERCEPTIVE ADVISORS LLC | 3,162,948 | 0 | 0 | 0 | For |
| Point72 | 0 | 3,080,715 | 0 | 0 | Against |
| Rubric Capital Management LP | 2,949,922 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 2,923,949 | 0 | 0 | Against |
| Woodline Partners LP | 2,508,892 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 2,480,155 | 0 | 0 | Against |
| Polar Capital Holdings Plc | 0 | 2,450,000 | 0 | 0 | Against |
| ORBIMED ADVISORS LLC | 0 | 2,278,760 | 0 | 0 | Against |
| Nuveen | 2,264,798 | 0 | 0 | 0 | For |
| DME Capital Management, LP | 2,208,920 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 0 | 2,084,636 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 0 | 2,024,948 | 0 | 0 | Against |
| IMPAX ASSET MANAGEMENT LLC | 0 | 2,000,000 | 0 | 0 | Against |
| Clearbridge Investments, LLC | 0 | 1,860,540 | 0 | 0 | Against |
| T. Rowe Price | 0 | 1,830,527 | 0 | 0 | Against |
Institutional-manager reports, all 245 managers: 114,302,908 for, 127,211,137 against, 63,894,716 abstained, 4,971 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 99.9% for (September 10, 2024 meeting) unchanged
Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Roivant's independent registered public accounting firm for Roivant's fiscal year ending March 31, 2026, to appoint Ernst & Young LLP as auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for Roivant's fiscal year ending March 31, 2026, and to authorize the Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as Roivant's auditor for Roivant's fiscal year ending March 31, 2026.
Roivant Sciences Ltd.’s own tally for this item (“2. The appointment of Ernst & Young LLP ("EY") to serve as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2026, and to appoint EY as the Company's auditor for statutory p”): 628,068,956 for, 479,264 against — passed, per its Form 8-K filed September 11, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(2) Shareholders ratified the appointment of Ernst & Young LLP ("EY") to serve as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2026, and to appoint EY as the Company's auditor for statutory purposes under the Bermuda Companies Act 1981, as amended…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the votes cast (“majority of the votes cast”).
Also reported under other wordings, matched to the same row of Roivant Sciences Ltd.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Approve Ernst & Young LLP as Auditors and Authorize Board to Fix Their Remuneration” (4 managers, 510,219 for).
The 69 asset managers below reported 128,455,676 for, 174,310 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 38,008,324 | 0 | 0 | 0 | For |
| Fidelity | 33,946,980 | 0 | 0 | 0 | For |
| BlackRock | 17,505,672 | 0 | 0 | 0 | For |
| Morgan Stanley | 8,797,806 | 0 | 0 | 0 | For |
| State Street | 4,990,116 | 0 | 0 | 0 | For |
| Charles Schwab | 2,865,389 | 0 | 0 | 0 | For |
| TIAA | 2,217,521 | 0 | 0 | 0 | For |
| Transamerica | 2,078,277 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 2,000,000 | 0 | 0 | 0 | For |
| WisdomTree | 1,767,115 | 0 | 0 | 0 | For |
| Goldman Sachs | 1,660,066 | 0 | 0 | 0 | For |
| Dimensional | 1,562,980 | 0 | 0 | 0 | For |
| Equitable | 1,526,704 | 0 | 0 | 0 | For |
| TIFF INVESTMENT PROGRAM | 1,403,699 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,047,664 | 0 | 0 | 0 | For |
| Jackson National | 782,901 | 0 | 0 | 0 | For |
| Brighthouse | 733,500 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 571,010 | 0 | 0 | 0 | For |
| John Hancock | 422,733 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 395,758 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 376,695 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 338,181 | 0 | 0 | 0 | For |
| Northern Trust | 288,515 | 0 | 0 | 0 | For |
| BNY Mellon | 266,779 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 252,013 | 0 | 0 | 0 | For |
Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 682,229,832 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.57% |
| 2 | Fidelity | 4.98% |
| 3 | BlackRock | 2.57% |
| 4 | Morgan Stanley | 1.29% |
| 5 | State Street | 0.73% |
| 6 | Charles Schwab | 0.42% |
| 7 | TIAA | 0.33% |
| 8 | Transamerica | 0.30% |
| 9 | IMPAX FUNDS SERIES TRUST I | 0.29% |
| 10 | WisdomTree | 0.26% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | SB INVESTMENT ADVISERS (UK) LTD | 8.65% |
| 2 | Fidelity | 7.80% |
| 3 | VIKING GLOBAL INVESTORS LP | 4.44% |
| 4 | QVT Financial LP | 4.31% |
| 5 | Morgan Stanley | 4.07% |
| 6 | State Street | 1.93% |
| 7 | BlackRock | 1.82% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.09% |
| 9 | Two Seas Capital LP | 0.86% |
| 10 | Capital Group | 0.71% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Dexxon Holdings | 102,849,443 | 15.08% | Proxy statement (DEF 14A), table as of June 30, 2026 |
| FMR (Fidelity) | 77,981,253 | 11.43% | Form 13F, quarter ended March 31, 2026 |
| FMR LLC | 73,641,253 | 10.79% | Proxy statement (DEF 14A), table as of June 30, 2026 |
| BlackRock | 44,254,260 | 6.49% | Form 13F, quarter ended March 31, 2026 |
| Vanguard Group | 42,059,041 | 6.16% | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 40,693,386 | 5.96% | Schedule 13G, filed August 13, 2026 |
| Ramaswamy Vivek | 25,534,970 | 3.74% | Schedule 13G, filed May 6, 2026 |
| Mayukh Sukhatme President and Chief Investment Officer and Director | 20,104,996 | 2.95% | Proxy statement (DEF 14A), table as of June 30, 2026 |
| Matthew Gline Chief Executive Officer and Director | 18,758,353 | 2.75% | Proxy statement (DEF 14A), table as of June 30, 2026 |
| SB Investment Advisers (UK) Limited | 16,413,603 | 2.41% | Schedule 13G, filed February 17, 2026 |
Percentages above are of 682,229,832 shares outstanding, as reported by Roivant Sciences Ltd. on its Form 10-Q dated June 30, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Roivant Sciences Ltd.'s shareholder meeting held September 10, 2025, in the 2025-2026 proxy season, 295 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,802 separate fund positions. On the most widely held item on that ballot — To cast a non-binding, advisory vote to approve the compensation of our named executive… — Roivant Sciences Ltd.'s filing reports the proposal as approved, with 61% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Roivant Sciences Ltd.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on September 11, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Roivant Sciences Ltd.’s 10-Q dated June 30, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Roivant Sciences Ltd. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Roivant Sciences (ROIV) 2025 Annual Meeting (2025-2026 season)”, https://proxyvotesnow.com/company/roivant-sciences-ltd/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.